USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Development of a Selectively Current-permeable Osteogenic Pedicle…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
1248546
Solicitation Year:
2012
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
OsteoVantage, Inc
535 W. Research Center Boulevard Suite 135, M/S 2600 Fayetteville, AR 72701-6948
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2013
Title: SBIR Phase I: Development of a Selectively Current-permeable Osteogenic Pedicle Screw Surface for Vertebral Fusion
Agency: NSF
Contract: 1248546
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project will develop a selectively direct-current permeable pedicle screw surface for use with patent-pending osteogenic spinal fusion instrumentation. New bone matrix more rapidly incorporates the bone graft material in the presence of an electric field to form a robust, biomechanically sound, intersegmental union. As the screw transmits current into the bone, peri-screw anchorage strength is also increased because of the local osteogenic effects. Pedicle screw loosening is a factor that contributes to clinically unacceptable failure rate (20-40%) associated with spinal fusion surgery. Based on preliminary work, the proposed instrumentation system has the potential to significantly improve outcomes by increasing fusion rate and robustness. Precise control of the electric field delivered through the pedicle screws is necessary to optimize the osteogenic capabilities. The broader impact/commercial potential of this project is the development of commercially available osteogenic instrumentation with the potential to improve surgical outcomes, thus reducing the high incidence of additional surgery, chronic pain and cost associated with failed fusion. In future iterations, it could potentially be used to accelerate fracture repair of the skull, face, and other sites. Because bone repair mechanisms are similar across species, it may one day offer veterinary orthopedic surgeons a means to help their animal patients.

Principal Investigator:

Matthew MacEwan
4795712592
matt.macewan@osteovantage.com

Business Contact:

Matthew MacEwan
4795712592
matt.macewan@osteovantage.com
Small Business Information at Submission:

OsteoVantage, Inc
535 W. Research Center Boulevard Suite 135, M/S 2600 Fayetteville, AR 72701-6948

EIN/Tax ID: 454521503
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes